Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of menthone to preparation of medicine for treating rheumatoid arthritis

A technology for rheumatoid and arthritis, applied in the field of molecular biology, can solve problems such as toxicity and achieve the effect of less toxicity

Pending Publication Date: 2021-05-07
SUZHOU UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the traditional Chinese medicine ingredient commonly used to treat RA is tripterygium wilfordii, but it has certain toxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of menthone to preparation of medicine for treating rheumatoid arthritis
  • Application of menthone to preparation of medicine for treating rheumatoid arthritis
  • Application of menthone to preparation of medicine for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: Menthone inhibits type I interferon signaling pathway

[0032] In previous studies, it was found that the type 1 interferon signaling pathway was activated in the local joints of rheumatoid arthritis model mice. When the type 1 interferon signaling pathway was inhibited, the symptoms of rheumatoid arthritis model mice were alleviated. Therefore, type 1 interferon may be an important target for the treatment of rheumatoid arthritis.

[0033] In order to explore whether Menthone can regulate the type I interferon signaling pathway, 2fTGH cells were plated on 12-well cell culture plates (about 0.5×10 6 / well), Menthone (10, 100 μM) was added, and an equal volume of DMSO was added to the negative control group (Ctrl). After incubating at 37°C for 24 hours, the cells were lysed with Trizol, and then the total RNA in the cells was extracted and reverse-transcribed into cDNA. The mRNA level of Ifit1, an important interferon-stimulated gene (ISGs) downstream of the...

Embodiment 2

[0036] Example 2: Menthone down-regulates Tyk2 protein level, a key protein of type I interferon

[0037] In order to further analyze the specific mechanism of Menthone regulating the type I interferon signaling pathway, 2fTGH cells were plated on a 12-well cell culture plate (about 0.5×10 6 / well), Menthone (100 μM) was added, and an equal volume of DMSO was added to the negative control group (Ctrl). After incubating at 37°C for 24 hours, cells were lysed with NP-40 lysate to prepare protein samples, electrophoresed by SDS-PAGE, transferred to PVDF membrane, blocked with 5% skimmed milk powder at room temperature for 1 hour, added primary antibody and incubated overnight at 4°C, PBST After washing, the secondary antibody was added to incubate at room temperature for 1 h. After washing with PBST, a luminescent substrate was added for exposure, development and fixation. The result is as image 3 shown.

[0038] image 3 The results showed that Menthone can significantly do...

Embodiment 3

[0039] Example 3: Menthone down-regulates protein levels by up-regulating Tyk2 ubiquitination, thereby inhibiting the type 1 interferon signaling pathway

[0040] In order to further analyze the specific mechanism of Menthone regulating Tyk2, 2fTGH cells were plated on 12-well cell culture plates (about 0.5×10 6 / well), the cells were transfected with the Flag-UB plasmid, and after 48 hours, the cells were treated with Menthone (100 μM), and an equal volume of DMSO was added to the negative control group (Ctrl). Incubate at 37°C for 24h. Cells were lysed with NP-40 lysate, protein samples were prepared, endogenous Tyk2 protein was enriched by co-immunoprecipitation (IP), electrophoresed by SDS-PAGE, transferred to PVDF membrane, 5% skimmed milk powder at room temperature Block for 1 hour, add primary antibody and incubate overnight at 4°C. After washing with PBST, add secondary antibody and incubate at room temperature for 1 hour. After washing with PBST, add luminescent subs...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, and discloses an application of menthone to preparation of a medicine for treating rheumatoid arthritis. A collagen-induced rheumatoid arthritis mouse model (CIA) proves that the menthone can effectively relieve the rheumatoid arthritis symptom by down-regulating the inflammatory factor level in a joint inflammation part and blood cells and regulating different subtype T cells to be in balance, and has a good anti-rheumatoid arthritis effect. The menthone can be used for preparing the medicine for treating the rheumatoid arthritis, and a new direction is provided for seeking the safe and effective medicine for resisting the rheumatoid arthritis.

Description

technical field [0001] The invention relates to the technical field of molecular biology, in particular to the application of a natural plant component menthone (Menthone) in the preparation of medicines for treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (RA) is a common clinical autoimmune disease. The clinical symptoms of patients mainly manifested as local joint inflammation and cartilage destruction. The global incidence of RA is 0.5% to 1.0%, and it can occur at any age. If RA patients fail to receive effective treatment in time, their condition will gradually worsen, eventually leading to joint deformity and loss of function, leading to disability and affecting the daily life ability of patients. [0003] In the past ten years, the treatment of RA has been greatly developed. However, because its pathogenesis is still unknown, there is no ideal method to completely cure RA. Clinically, the methods for treating RA are generally divi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/122A61K9/00A61K9/14A61P29/00A61P19/02
CPCA61K31/122A61K9/0019A61K9/14A61P29/00A61P19/02
Inventor 郑慧陈相洁龚方苑龚政
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com